Subject Areas on Research
- A blood spot method for detecting fumonisin-induced changes in putative sphingolipid biomarkers in LM/Bc mice and humans.
- Acylation of naturally occurring and synthetic 1-deoxysphinganines by ceramide synthase. Formation of N-palmitoyl-aminopentol produces a toxic metabolite of hydrolyzed fumonisin, AP1, and a new category of ceramide synthase inhibitor.
- Alteration in sphingolipid metabolism: bioassays for fumonisin- and ISP-I-like activity in tissues, cells and other matrices.
- Alteration of tissue and serum sphinganine to sphingosine ratio: an early biomarker of exposure to fumonisin-containing feeds in pigs.
- Characterization of cell-cycle arrest by fumonisin B1 in CV-1 cells.
- Chronic toxicity of fumonisins from Fusarium moniliforme culture material (M-1325) to mink.
- Dietary fumonisin B1 induces disruption of sphingolipid metabolism in Sprague-Dawley rats: a new mechanism of nephrotoxicity.
- Effects of feeding Fusarium moniliforme culture material, containing known levels of fumonisin B1, on the young broiler chick.
- Evidence for disruption of sphingolipid metabolism as a contributing factor in the toxicity and carcinogenicity of fumonisins.
- Evidence for fumonisin inhibition of ceramide synthase in humans consuming maize-based foods and living in high exposure communities in Guatemala.
- Exposure to fumonisins and the occurrence of neural tube defects along the Texas-Mexico border.
- Fumonisin B1 alters sphingolipid metabolism and disrupts the barrier function of endothelial cells in culture.
- Fumonisin B1 consumption by rats causes reversible, dose-dependent increases in urinary sphinganine and sphingosine.
- Fumonisin B1 inhibits sphingosine (sphinganine) N-acyltransferase and de novo sphingolipid biosynthesis in cultured neurons in situ.
- Fumonisin inhibition of de novo sphingolipid biosynthesis and cytotoxicity are correlated in LLC-PK1 cells.
- Fumonisin toxicity and sphingolipid biosynthesis.
- Fumonisins and fumonisin analogs as inhibitors of ceramide synthase and inducers of apoptosis.
- Fumonisins disrupt sphingolipid metabolism, folate transport, and neural tube development in embryo culture and in vivo: a potential risk factor for human neural tube defects among populations consuming fumonisin-contaminated maize.
- Hydrolyzed fumonisins HFB1 and HFB2 are acylated in vitro and in vivo by ceramide synthase to form cytotoxic N-acyl-metabolites.
- In vitro toxicology of fumonisins and the mechanistic implications.
- Increases in serum sphingosine and sphinganine and decreases in complex sphingolipids in ponies given feed containing fumonisins, mycotoxins produced by Fusarium moniliforme.
- Inhibition of sphingolipid biosynthesis by fumonisins. Implications for diseases associated with Fusarium moniliforme.
- Prevention of fumonisin B1-induced neural tube defects by folic acid.
- Role of dietary sphingolipids and inhibitors of sphingolipid metabolism in cancer and other diseases.
- Sphingolipid biosynthesis de novo by rat hepatocytes in culture. Ceramide and sphingomyelin are associated with, but not required for, very low density lipoprotein secretion.
- Sphingolipid metabolism: roles in signal transduction and disruption by fumonisins.
- Sphingolipids as biomarkers of fumonisin exposure and risk of esophageal squamous cell carcinoma in china.
- Sphingosine-1-phosphate phosphohydrolase regulates endoplasmic reticulum-to-golgi trafficking of ceramide.
- The effect of fumonisin B1 on developing chick embryos: correlation between de novo sphingolipid biosynthesis and gross morphological changes.
- The kinetics of urinary fumonisin B1 excretion in humans consuming maize-based diets.
- Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors.
- Urinary fumonisin B1 and estimated fumonisin intake in women from high- and low-exposure communities in Guatemala.